
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is in positive financial standing with a strong outlook for future growth in their contract development and manufacturing services, with an estimated revenue value of over $100 million in late stage and site transfer projects. The company has a growing pipeline of over 30 active projects, which is expected to have a meaningful impact on financial results starting in 2028. While there are risks to consider, such as failing to meet revenue and earnings estimates, the recent commercial progress and strategic execution by Lifecore make it a compelling investment opportunity with potential for significant outperformance in the next 3 to 5 years.
Bears say
Lifecore Biomedical is showing strong growth potential with its third manufacturing agreement in just five months, and it's acquisition of new customers. As an established and fully-integrated CDMO, the company is expected to see an increase in revenue in both its CDMO and HA manufacturing categories, making it a strong investment opportunity.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares